Medical Sciences Correction for “Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma,” by Altaf A. Dar, Vladimir Bezrookove, Mehdi Nosrati, Ryan Ice, John M. Patino, Edith M. Vaquero, Brian Parrett, Stanley P. Leong, Kevin B. Kim, Robert J. Debs, Liliana Soroceanu, James R. Miller III, Pierre-Yves Desprez, James E. Cleaver, Nathan Salomonis, Sean McAllister, and Mohammed Kashani-Sabet, which published August 15, 2022; 10.1073/pnas.2206824119 (Proc. Natl. Acad. Sci. U.S.A. 119, e2206824119).
The authors note that Fig. 1 appeared incorrectly. The corrected figure and its legend appear below. The online version has been corrected.
Fig. 1.
Effects of single or combination drug treatments in various melanoma PDX models. Antitumor activity of various single drugs or drug combinations on the following PDX models in vivo, respectively: MM-302 (A); MM-300 (B); MM-337 (C); MM-358 (D); MM-313 (E); MM-386 (F); and MM-505 (G). (H) CI values for the bromo/cobi combination in different PDX models.